# AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

> **NCT00513071** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** saracatinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00513071
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513071, "AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00513071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*